Broad protection against avian influenza virus by using a modified vaccinia ankara virus expressing a mosaic hemagglutinin gene

Journal of Virology

Volumn 88, Issue 22, 2014, Pages 13300-13309

  Kamlangdee, Attapon ^a   Kingstad Bakke, Brock ^a   Anderson, Tavis K ^b   Goldberg, Tony L ^a   Osorio, Jorge E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b GEORGIA SOUTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MODIFIED VACCINIA ANKARA VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; DRUG CARRIER; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; HYBRID PROTEIN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; CLADISTICS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HEMAGGLUTININ GENE; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; SEASONAL INFLUENZA; SPECIES DIVERSITY; VACCINATION; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS PROTECTION; DISEASE MODEL; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; SURVIVAL ANALYSIS; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; DISEASE MODELS, ANIMAL; DRUG CARRIERS; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84908374176     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01532-14     Document Type: Article

References (42)

1. Meltzer MI, Cox NJ, Fukuda K. 1999. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg. Infect. Dis. 5:659-671. http://dx.doi.org/10.3201/eid0505.990507.
2. Lazzari S, Stohr K. 2004. Avian influenza and influenza pandemics. Bull. World Health Organ. 82:242.
3. Allen PJ. 2006. The world awaits the next pandemic: will it be H5N1, the 'bird flu'? J. Child Health Care 10:178-187. http://dx.doi.org/10.1177/1367493506066479.
4. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. 2006. Strategies for mitigating an influenza pandemic. Nature 442: 448-452. http://dx.doi.org/10.1038/nature04795.
5. Lipsitch M, Cohen T, Murray M, Levin BR. 2007. Antiviral resistance and the control of pandemic influenza. PLoS Med. 4:e15. http://dx.doi.org/10.1371/journal.pmed.0040015.
6. Lipsitch M, Riley S, Cauchemez S, Ghani AC, Ferguson NM. 2009. Managing and reducing uncertainty in an emerging influenza pandemic. N. Engl. J. Med. 361:112-115. http://dx.doi.org/10.1056/NEJMp0904380.
7. Gandon S, Mackinnon MJ, Nee S, Read AF. 2001. Imperfect vaccines and the evolution of pathogen virulence. Nature 414:751-756. http://dx.doi.org/10.1038/414751a.
8. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Low-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pollabauer EM, Kistner O, Barrett PN, Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. 2008. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358:2573-2584. http://dx.doi.org/10.1056/NEJMoa073121.
9. Wright PF. 2008. Vaccine preparedness-are we ready for the next influenza pandemic? N. Engl. J. Med. 358:2540-2543. http://dx.doi.org/10.1056/NEJMp0803650.
10. Kunisaki KM, Janoff EN. 2009. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis. 9:493-504. http://dx.doi.org/10.1016/S1473-3099(09)70175-6.
11. Peck FB, Jr. 1968. Purified influenza virus vaccine. A study of viral reactivity and antigenicity. JAMA 206:2277-2282.
12. Mostow SR, Hopkins JA, Wright PF. 1979. Behavior of vaccine revertants of temperature-sensitive mutants of influenza virus in ferret tracheal organ culture. Infect. Immun. 26:193-196.
13. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Lower J, Osterhaus AD, Sutter G, Rimmelzwaan GF. 2009. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J. Infect. Dis. 199:405-413. http://dx.doi.org/10.1086/595984.
14. Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, Savidis-Dacho H, Zips ML, Crowe BA, Kreil TR, Ehrlich HJ, Barrett PN, Falkner FG. 2011. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 6:e16247. http://dx.doi.org/10.1371/journal.pone.0016247.
15. Drexler I, Staib C, Sutter G. 2004. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr. Opin. Biotechnol. 15:506-512. http://dx.doi.org/10.1016/j.copbio.2004.09.001.
16. Brewoo JN, Powell TD, Jones JC, Gundlach NA, Young GR, Chu H, Das SC, Partidos CD, Stinchcomb DT, Osorio JE. 2013. Crossprotective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine 31: 1848-1855. http://dx.doi.org/10.1016/j.vaccine.2013.01.038.
17. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1(1):e00018-10. http://dx.doi.org/10.1128/mBio.00018-10.
18. Chen Y, Qin K, Wu WL, Li G, Zhang J, Du H, Ng MH, Shih JW, Peiris JS, Guan Y, Chen H, Xia N. 2009. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J. Infect. Dis. 199:49-58. http://dx.doi.org/10.1086/594374.
19. Wu KW, Chien CY, Li SW, King CC, Chang CH. 2012. Highly conserved influenza A virus epitope sequences as candidates of H3N2 flu vaccine targets. Genomics 100:102-109. http://dx.doi.org/10.1016/j.ygeno.2012.06.003.
20. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. 2007. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 13:426-435. http://dx.doi.org/10.3201/eid1303.061125.
21. Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Kou Z, Chan CC, Guo Y, Jiang S, Zheng BJ, Zhou Y. 2010. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol. J. 7:9. http://dx.doi.org/10.1186/1743-422X-7-9.
22. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, Yu AL, Wong CH, Ho DD. 2008. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 105:13538-13543. http://dx.doi.org/10.1073/pnas.0806901105.
23. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, Clark SL, Backus K, Perry JR, Seaman MS, Carville A, Mansfield KG, Szinger JJ, Fischer W, Muldoon M, Korber B. 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16:319-323. http://dx.doi.org/10.1038/nm.2089.
24. + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16:324-328. http://dx.doi.org/10.1038/nm.2108.
25. Santra S, Muldoon M, Watson S, Buzby A, Balachandran H, Carlson KR, Mach L, Kong WP, McKee K, Yang ZY, Rao SS, Mascola JR, Nabel GJ, Korber BT, Letvin NL. 2012. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 428:121-127. http://dx.doi.org/10.1016/j.virol.2012.03.012.
26. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13:100-106. http://dx.doi.org/10.1038/nm1461.
27. Gogolak P, Simon A, Horvath A, Rethi B, Simon I, Berkics K, Rajnavolgyi E, Toth GK. 2000. Mapping of a protective helper T cell epitope of human influenza A virus hemagglutinin. Biochem. Biophys. Res. Commun. 270:190-198. http://dx.doi.org/10.1006/bbrc.2000.2384.
28. Earl PL, Moss B, Wyatt LS, Carroll MW. 2001. Generation of recombinant vaccinia viruses. Curr. Protoc. Protein Sci. Chapter 5:Unit 5.13. http://dx.doi.org/10.1002/0471140864.ps0513s13.
29. Killian ML. 2008. Hemagglutination assay for the avian influenza virus. Methods Mol. Biol. 436:47-52. http://dx.doi.org/10.1007/978-1-59745-279-3_7.
30. Brown CC, Olander HJ, Senne DA. 1992. A pathogenesis study of highly pathogenic avian influenza virus H5N2 in chickens, using immunohistochemistry. J. Comp. Pathol. 107:341-348. http://dx.doi.org/10.1016/0021-9975(92)90009-J.
31. Bahgat MM, Kutkat MA, Nasraa MH, Mostafa A, Webby R, Bahgat IM, Ali MA. 2009. Characterization of an avian influenza virus H5N1 Egyptian isolate. J. Virol. Methods 159:244-250. http://dx.doi.org/10.1016/j.jviromet.2009.04.008.
32. Hafez MH, Arafa A, Abdelwhab EM, Selim A, Khoulosy SG, Hassan MK, Aly MM. 2010. Avian influenza H5N1 virus infections in vaccinated commercial and backyard poultry in Egypt. Poult. Sci. 89:1609-1613. http://dx.doi.org/10.3382/ps.2010-00708.
33. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2012. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336:1534-1541. http://dx.doi.org/10.1126/science.1213362.
34. El-Shesheny R, Kayali G, Kandeil A, Cai Z, Barakat AB, Ghanim H, Ali MA. 2012. Antigenic diversity and cross-reactivity of avian influenza H5N1 viruses in Egypt between 2006 and 2011. J. Gen. Virol. 93:2564-2574. http://dx.doi.org/10.1099/vir.0.043299-0.
35. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A. 2007. Ab and T cell epitopes of influenzaAvirus, knowledge and opportunities. Proc. Natl. Acad. Sci. U. S. A. 104:246-251. http://dx.doi.org/10.1073/pnas.0609330104.
36. Kaminski DA, Lee FE. 2011. Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design. Front. Immunol. 2:76. http://dx.doi.org/10.3389/fimmu.2011.00076.
37. Kaur K, Sullivan M, Wilson PC. 2011. Targeting B cell responses in universal influenza vaccine design. Trends Immunol. 32:524-531. http://dx.doi.org/10.1016/j.it.2011.08.007.
38. Howard MK, Sabarth N, Savidis-Dacho H, Portsmouth D, Kistner O, Kreil TR, Ehrlich HJ, Barrett PN. 2011. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 6:e23791. http://dx.doi.org/10.1371/journal.pone.0023791.
39. Price PJ, Torres-Dominguez LE, Brandmuller C, Sutter G, Lehmann MH. 2013. Modified vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine 31:4231-4234. http://dx.doi.org/10.1016/j.vaccine.2013.03.017.
40. Chiu C, Wrammert J, Li GM, McCausland M, Wilson PC, Ahmed R. 2013. Cross-reactive humoral responses to influenza and their implications for a universal vaccine. Ann. N. Y. Acad. Sci. 1283:13-21. http://dx.doi.org/10.1111/nyas.12012.
41. Liu S, Ji K, Chen J, Tai D, Jiang W, Hou G, Chen J, Li J, Huang B. 2009. Panorama phylogenetic diversity and distribution of type A influenza virus. PLoS One 4:e5022. http://dx.doi.org/10.1371/journal.pone.0005022.
42. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, Kent SJ. 2013. Crossreactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190:1837-1848. http://dx.doi.org/10.4049/jimmunol.1201574.